Gossamer Bio (GOSS) Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. BLZE
7. IBM
8. NKE
9. MU
10. ACN

Go back to Gossamer Bio (GOSS) Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA

Gossamer Bio Inc. (GOSS) Misses Q3 EPS by 11c

November 12, 2019 4:39 PM EST

Gossamer Bio Inc. (NASDAQ: GOSS) reported Q3 EPS of ($0.80), $0.11 worse than the analyst estimate of ($0.69).

Since the beginning of the third quarter, we have realized substantial progress advancing our diverse pipeline of four clinical-stage programs, said Sheila Gujrathi, M.D., Co-Founder and Chief Executive... More